Summary The tumour-associated antigen epithelial glycoprotein-2 (EGP-2) is a promising target for detection and treatment of a variety of human carcinomas. Antibodies to this antigen have been successfully used in patients for imaging of small-cell lung cancer and for adjuvant treatment of minimal residual disease of colon cancer. We describe here the isolation and complete characterization of high-affinity singlechain variable fragments (scFv) to the EGP-2 antigen. First, the binding kinetics of four murine whole antibodies directed to EGP-2 (17-1A, 323/A3, MOC-31 and MOC-1 61) were determined using surface plasmon resonance (SPR). The MOC-31 antibody has the lowest apparent off-rate, followed by MOC-161 and 323/A3. The V-genes of the two MOC hybridomas were cloned as scFv in a phage display vector and antigen-binding phage were selected by panning on recombinant antigen. The scFvs compete with the original hybridoma antibodies for binding to antigen and specifically bind to human carcinomas in immunohistochemistry. MOC-31 scFv has an off-rate which is better than those of the bivalent 17-1A and 323/A3 whole antibodies, providing it with an essential characteristic for tumour retention in vivo. The availability of these high-affinity anti-EGP-2 antibody fragments and of their encoding V-genes creates a variety of possibilities for their future use as tumour-targeting vehicles.
During colorectal carcinogenesis, a number of (membrane) antigens are up-regulated, mutated or differently processed, providing targets for (adjuvant) immunotherapy of the disease. Several tumour antigens have been described and used for targeting or as indicators of progression of disease [e.g. carcinoembryonic antigen (CEA), TAG72, c-erB2, (underglycosylated) MUC-1, p53]. The epithelial glycoprotein-2 (EGP-2, also named C017-lA antigen, KSA, EGP40 or Ep-CAM) is a tumour-associated antigen present on human simple epithelia and their derived tumours. The abundant expression of EGP-2 on a number of human carcinomas, its limited expression on the luminal side of normal non-squamous epithelia only and the fact that it is not shed into the circulation make this antigen a favourable target for imaging and immunotherapy of cancer. Murine antibodies to EGP-2 have been used in radioimmune detection trials (Balaban et al, 1991; Kosterink et al, 1995) , as well as in phase I and II clinical trials (Frodin et al, 1988) . The most successful study has been the treatment of minimal residual disease (MRD) in patients with Dukes' C colon carcinoma using the 17-1A antibody (Herlyn et al, 1979) . In this study (Riethmuller et al, 1994) , an overall 30% reduction in 5-year mortality was observed, proving that passive immunotherapy in an adjuvant setting may be as effective as chemotherapy.
Other therapeutic strategies based on the use of antibodies to EGP-2 have also been described. These include the recruitment and activation of T cells by using a fusion of an EGP-2-reactive antibody fragment with the bacterial superantigen staphylococcal enterotoxin A (Dohlsten et al, 1994) or by using bispecific antibodies, directed to both EGP-2 and the T-cell CD3 antigen (Kroesen et al, 1994) . In a different approach, the conjugation of anti-EGP-2 antibodies to different bacterial toxins has been shown to yield potent immunotoxins (LeMaistre et al, 1987; Zimmermann et al, 1997) . These (pre)clinical studies all underline the possibilities of using antibodies (in different format) to EGP-2 for (adjuvant) immunotherapy.
Careful experimental analysis of scFv variants of an anti-c-erB2 antibody with a range of affinities indicated that there is a clear correlation between affinity increase and enhanced tumour retention (Adams et al, 1993) . The availability of high-affinity recombinant anti-EGP-2 antibody fragments would therefore be highly desirable. Indeed, the potential use of such scFv antibody fragments for imaging of human carcinomas has already been demonstrated with a scFv directed to carcinoembryonic antigen (CEA; Begent et al, 1996) .
In this study, we first compared the binding kinetics of four murine whole antibodies [17-lA, 323/A3 (Edwards et al, 1986) MOC-31 and MOC-161 (Souhami et al, 1988) ] to the antigen EGP-2 using SPR in a BlAcore. Our results show that the MOC-31 antibody has by far the lowest off-rate of all antibodies tested;
MOC-161 has a similar off-rate to the 323/A3 antibody. The Vgenes of the two antibodies with lowest off-rate were cloned in scFv format and the off-rate and specificity of the scFv antibody fragments determined. 
MATERIALS AND METHODS Anti-EGP-2 antibodies
The antibodies 17-lA, chimeric 17-lA and 323/A3 were a kind gift from Dr SO Warnaar (Centocor, Leiden, The Netherlands). The two hybridomas cloned in this study and MOC-161 (IgG2aIK)] were generated by hybridoma technology (Souhami et al, 1988) . Bis-1 bispecific antibody (Kroesen et al, 1994 ) is produced by a quadroma clone made from the hybridomas MOC-31 (anti EGP-2) and RIV-9 (anti CD3) and was kindly donated by Dr B-J Kroesen (University Hospital Groningen).
Kinetic measurement using SPR in a BlAcore Recombinant EGP-2 was expressed in the baculovirus system as described [Strassburg et al, 1992; Helfrich et al, 1994 ; a kind gift of Professor D Herlyn (the Wistar Institute)]. The antigen was covalently coupled to a CM-5 sensorchip (Pharmacia, Uppsala, Sweden) via free amide chemistry, resulting in a surface of 350 resonance units (RU). All kinetic measurements were performed on this antigen surface. To determine the binding kinetics of different whole antibodies (17-lA, chimeric 17-lA, 323/A3, MOC-161, MOC-31 and Bis-1) and antibody fragments (MOC-31 scFv and MOC-161 scFv), this 'low-density' EGP-2 surface was saturated with antibody (at 200 nM) or antibody fragment using a flow rate of 5 ,ul min-' (Figure 1 ). Dissociation rates (K 0) were then calculated using the BlAevaluation software (Pharmacia) from the sensorgrams depicted in Figure 1 . The off-rates were determined by curve fitting on the time interval t = 315-320 s, with one exception: because of its very low value, it was impossible to determine the off-rate of the MOC-31 whole antibody in this time period. In this case, an average value of three independent fittings on different parts of the curve is given. As the kinetics of binding of the MOC-161 whole antibody were determined with concentrated hybridoma supernatant, the antibody concentration was unknown and the sensorgram is not shown. However, the same experimental set-up was used, in which the antigen surface was saturated with antibody. All measurements were carried out at room temperature. aBecause of the very high off-rates of these antibodies, the low-density EGP-2 surface could not be saturated with antibody ( Figure 1 ). These off-rates are therefore understimations of the true values, which may account for the unexpectedly observed difference.
High-affinity phage antibodies to the epithelial glycoprotein-2 1409 The half-life of the antibody-antigen complex was calculated as t 12 = 1n2/Koff (Table 1) .
Cloning vectors pCANTAB6 is a derivative of pHENI , carrying an additional stretch of six histidine residues [to allow immobilized metal ion affinity chromatography (IMAC) purification] upstream of the c-myc-derived sequence (which allows detection with the 9E10 antibody). ScFv cassettes are cloned as SfiI-NotI fragments in frame with the upstream pelB leader sequence and LacZ promoter and with the downstream bacteriophage gene III. The vector also contains an amber stop codon between the c-myc sequence and gene III, allowing production of soluble scFv in a non-suppressor strain of Escherichia coli. Plasmid pUC I 19-polyHIS6myc (a kind gift from Dr AD Griffiths) is a derivative of pUC1 19 and carries 5'-SfiI/NcoI and 3'-NotI cloning sites. ScFv cassettes are cloned in frame with an upstream LacZ promoter and pelB signal sequence and a downstream cassette of a c-myc-derived sequence and six histidine residues. As in the related pUC 1 19-His6mycXba , the bacteriophage gene III is absent.
Escherichia coli strain TG 1: K12, D(lac-pro), supE, thi, hsdD5IF' traD36, proA+B+, laclq, lacZDM15 Oligonucleotides Primers used for the amplification of variable parts of the heavy chain (VH) and of the light chain (VL) of murine immunoglobulin genes, for the synthesis of the linker fragment and for reamplification of the assembled scFv cassettes are listed in Table 2 . All primers were purchased from Eurogentec (Liege, Belgium).
Cloning of immunoglobulin genes
Total cellular RNA was extracted from 107 cells of each of the hybridoma cell lines MOC-31 and MOC-161 by means of the RNazol method (Biotecx Laboratories, Houston, TY, USA). After precipitation, the RNA was dissolved in 20 ,l of water and used as template to synthesize cDNA using random hexamer primers (Promega, Madison, WJ, USA) in a 50-gl reverse transcriptase (RT) reaction according to standard procedures. Variable domains of both heavy (VH) and light chain (VL) genes were then amplified British Journal of Cancer (1998) 78(11), [1407] [1408] [1409] [1410] [1411] [1412] [1413] [1414] [1415] [1416] 0 Cancer Research Campaign 1998 1410 RC Roovers et al from cDNA using heavy of light chain-specific primer mixes (see Table 2 ) and assembled with a linker sequence encoding a 15-residue Gly/Ser sequence by means of Splice Overlap Extension PCR, as described by Clackson et al (1991) . The assembled cassette was gel purified, cut with the restriction enzymes Sfil and NotI and gel purified again. ScFv cassettes were cloned into Sfi1NotI-digested pCANTAB6 DNA and the ligation mix was electroporated into E. coli TGI using standard procedures. Bacteria were plated on 2xTY [1.6% (w/v) trypton, 1% (w/v) yeast extract, 0.5% (w/v) sodium chloride] plates, supplemented with 2% (w/v) glucose and 100 gg ml-l ampicillin, and harvested after overnight growth to form a library of transformants.
Selection on recombinant, baculovirus-expressed EGP-2 by panning in immunotubes A small repertoire of transformed bacteria (approximately 106 in size) containing the MOC-31 scFv ligated into pCANTAB6 was rescued with helper phage M13K07 and phage were panned for binding to the antigen EGP-2 [coated at 10 gg ml' concentration using immunotubes (Maxisorb; Nunc/Life Technologies, Gaithersburg, ND, USA)] as described previously (Marks et al, 1991) . Two rounds of selection were performed; after each round, single clones were screened for binding to antigen in enzymelinked immunosorbent assay (ELISA) as described (see below).
ELISA and competition ELISA
To identify binding scFvs from the individual clones selected for further analysis, an ELISA using soluble scFv was performed on purified, recombinant EGP-2. Individual bacterial clones were picked and production of soluble scFv was induced by activation of the upstream LacZ promoter with isopropyl-p-D-thiogalactopyranoside (IPTG) as described by Marks et al (1991) . ELISA plates (Costar, Cambridge, MA, USA) were coated overnight with 1 jg ml EGP-2 in phosphate-buffered saline (PBS), washed three times with PBS-T [PBS, 0.5% (v/v) Tween-20], three times with PBS and blocked for 1 h at room temperature (RT) with 2% MPBS [2% (w/v) Marvel -skimmed milk powder -in PBS]. After blocking, induced bacterial supernatants were added [50% (v/v) For competition ELISA, scFv antibody fragments expressed as pIll fusions on the tip of bacteriophage were detected in the presence of excess whole antibody (because of cross-reactivity of antimouse Ig antibodies -used to detect the 9E10 antibody bound to scFvs -with the original whole murine antibodies, this test was not performed with soluble scFvs). Briefly, MOC-31 and MOC-161 phage were rescued with helper phage M13KO7 as described previously (Marks et al, 1991) . Approximately 1010 colony-forming units (cfu) of phage were then mixed with 100 jl of hybridoma supernatant and simultaneously added to different wells of an antigen-coated ELISA plate. Bound phage were detected with a sheep polyclonal antiserum [sheep anti-fd; Pharmacia; 0.02% (v/v) in 2% MPBS], peroxidase-conjugated rabbit anti-goat immunoglobulins [Dako, Glostrup, Denmark; 0.05% (v/v) in 2% MPBS] and stained with TMB/hydrogen peroxide.
Sequencing
The nucleotide sequences of both the MOC-31 and MOC-161 scFvs were determined using the dideoxy sequencing method of Sanger. Products of the sequencing reaction were analysed on a semiautomated sequencer (Alf Express; Pharmacia). Oligonucleotides used were pUC-FOR and pUC-REV (Table 2 ).
Production and purification of soluble scFv
To produce large quantities of both antibody fragments, scFv cassettes were subcloned as SfiI/Not I fragments into pUC-119polyHIS6myc, lacking the bacteriophage gene III. This expression plasmid is less toxic to bacteria owing to expression of gene III during induction and thus a higher yield of antibody. Both the supematant and the periplasmic fraction of bacteria, grown at three different temperatures and harvested after two different time intervals (growth at 20°C, 30°C and 37°C; induction during 4 h or overnight), were first tested for the amount of functional scFv in ELISA.
Five hundred millilitres of 2xTY/AIG [2xTY, supplemented with 100 jg ml-' ampicillin and 2% (w/v) glucose] was inoculated with E. coli TG1 harbouring MOC-31 or MOC-161 scFv in pUC119-polyHIS6myc and bacteria were grown at 37'C to an OD600 of 1.0. Bacteria were spun down, resuspended in 2xTY containing 100 jig ml-1 ampicillin and IPTG to a final concentration of 1 mm and grown for 4 h at 30°C while shaking. After 4 h of induction, bacteria were pelleted and periplasmic fractions were prepared by resuspending the pellet in 8 ml of ice-cold TES (200 mm Tris-HCl, 0.5 mM EDTA, 500 mm sucrose; pH 8.0), adding 12 ml of ice-cold diluted TES (1:3 in water), and incubated on ice for 30 min. Bacteria were spun down (4500 r.p.m., 15 min, 4°C) and the supernatant was collected. The cell pellet was resuspended again in 10 ml of TES, 150 jl of 1 M magnesium sulphate was added and the mix was incubated on ice for 30 min. Cells were spun down again and the supernatant was added to the first periplasmic preparation. EDTA was largely removed by means of dialysis against 20 mm Tris-HCl, 100 mm sodium chloride (pH 8.0). The histidine-tagged scFv fragments were further purified by means of IMAC on Talon resin (Clontech, Palo Alto, CA, USA) using elution with 100 mm imidazole, according to the manufacturer's protocol. Monomeric and dimeric forms of the scFvs were separated by gel filtration chromatography (on a Superdex column; Pharmacia) using a Biologic Apparatus (BioRad, Hercules, USA). Different fractions were finally analysed by means of SDS polyacrylamide gel electrophoresis (SDS-PAGE).
Immunohistochemical analysis of scFv clones
Six-micron frozen sections (of normal colon epithelium, melanoma and colon carcinoma) were cut, mounted on 3-aminopropyltriethoxy silane (APTS)-coated glass slides, force dried on air and fixed in acetone on ice for 15 min. Slides were force dried on air again, bacterial periplasmic preparations were added [50% (v/v) High-affinity phage antibodies to the epithelial glycoprotein-2 1411 RESULTS Comparison of the binding kinetics of different anti-EGP-2 murine whole antibodies One of the most important characteristics of antibodies is the rate with which they detach from bound antigen, given by the off-rate of the molecule (Koff). To select the antibody with the most promising properties for tumour targeting, we set out to screen the binding characteristics (and in particular the off-rate) of four monoclonal antibodies directed to the pan-carcinoma antigen EGP-2: 17-1A (and a chimeric version thereof), 323/A3, MOC-31 and MOC-161. The on-and off-rates of these (whole) antibodies were determined using a BIAcore2000 (Figure 1 and Table 1 ). The off-rate we measured for MOC-3 1 whole antibody is the lowest of all antibodies tested; it would yield a half-life of the antibody-antigen complex in solution of approximately 4 h. The antibody that has been most often used for clinical applications, 17-lA, has an apparent off-rate which translates into an antibody-antigen complex half-life of less than a minute (Table 1) . Antibody MOC-161 has an apparent off-rate which is similar to that of 323/A3 antibody. These off-rates are apparent values; they are most likely underestimates of the real off-rates, because of the bivalent nature of the antibodies causing rebinding events during dissociation of antibody from the antigen surface (Nieba et al, 1996) and they are influenced by the experimental conditions used to measure them. However, because all antibodies tested recognize the same epitope on EGP-2 and the same experimental set-up was used for all, the relative ranking will be correct.
To obtain absolute values for the binding kinetics of the best antibody, MOC-3 1, it was necessary to determine those of the monovalent antibody Bis-1, a bispecific antibody with one MOC-31 binding site and one anti-CD3 site. The same antigen surface bound approximately twice the amount (in RU) of Bis-1 when compared with MOC-3 1 (Figure 1 ). This indicates that, despite the use of a low-density EGP-2 surface, simultaneous binding of both Fab arms was a very frequent event for all bivalent molecules, which may be partially explained by the flexibility of the antigen surface. As expected, the off-rate of Bis-1 was shown to be higher (approximately fivefold: Table 1) than that of MOC-3 1 antibody. It can be concluded that, because MOC-3 1 has the lowest off-rate of the antibodies tested, followed by MOC-161 and 323/A3 (Table  1) , the MOC antibodies were the most promising starting points for the cloning of recombinant antibody fragments.
Cloning of recombinant scFv antibody fragments
The genes encoding the variable parts of heavy (VH) and light chain (VL) of the hybridomas MOC-31 and MOC-161 were amplified by means of reverse transcriptase polymerase chain reaction (RT-PCR) and assembled to form a scFv construct with a 15-residue (Gly4Ser)3 linker. The set of oligonucleotides used in this study was similar to the one used by Clackson et al (1991) , with one important improvement: a redesigned set of MVKBACK primers was used, which was expanded to five oligonucleotides on the basis of the collection of murine VK genes present in the Kabat (1991) database (Kabat et al, 1991;  Table 2 ). Extensive tests indicate that this new primer set successfully amplifies over 95% of all rearranged murine Vic genes (AR Pope personal communication). For MOC-3 1, a 250-nt by-product was preferentially found during amplification of the Vic domain when using a mix of MVKBACK primers. However, when all BACK primers were used separately in different reactions, the band of expected size (approximately 340 nt) was predominantly found (>90% of the PCR product) with primers MVKCBACK and MVKDBACK.
ScFv cassettes were cloned into phagemid vector pCANTAB6, which allows expression either as fusion protein to the bacteriophage gene III product or as soluble scFv in a non-suppressor strain of E. coli. For MOC-161, binding scFv were detected by means of ELISA directly after cloning, in a frequency of 11/90. This is a typical frequency when rescuing V-genes from hybridomas (Clackson et al, 1991) . For the MOC-31 hybridoma, however, the initial screen did not reveal any active scFvs. Therefore, a small scFv antibody repertoire (approximately 106 The V-gene nucleic acid sequences of both antibody fragments were determined using a semiautomated sequencer and sequences were submitted to GenBank (accession numbers: U80187-U80190). The primers used to amplify light chain genes were: for MOC-3 1, MVKCBACK (consistent with the results of the primary amplification of the light chain gene) and MJKIFONX; for MOC-161, these were MVKDBACK and MJK5FONX. A comparison of the amino acid sequences of MOC-31 and -161 with those of the 323/A3 and 17-lA antibodies is shown in Table 3 (for both MOC antibodies, primer-encoded regions are depicted in lower-case letters). Both hybridomas use very different VH and VK genes. The MOC-31 VH and Vic gene segments are members of the Kabat II and VII family respectively; for MOC-161, the designated families are VII and XIV. Both antibody VH genes use the same germline Jsegment, being either JH2 or JH4 (both encoding a 'DY' sequence in the C-terminal end of the CDR3 loop; Table 3 ). Besides these two residues, the antibodies share an additional two residues ('KG') in the C-terminal half of the VH-CDR3, which are most likely not encoded by any D-segment. Production and purification of recombinant scFv fragments ScFv antibody production was induced in bacteria harbouring the MOC-31 and -161 scFv cassettes in pUC1 19-polyHIS6myc. The highest amount of antibody (as judged by titrating the fractions in ELISA) was observed in the periplasm of bacteria after 4 h of induction at 300C (data not shown). These conditions were therefore used to produce soluble scFv for purification. ScFv fragments were then purified from a periplasmic extract of a large-scale induced culture of bacteria by means of IMAC. This purification procedure permitted both antibody fragments to be recovered in highly pure form (purity > 95%; Figure 2 ). As scFv fragments (Figure l B and Table 1 ). The off-rate of monovalent MOC-31 scFv (3.4 x 104 s ') only differs by a factor of less than 1.5 from that of the original monovalent interaction (Bis-I antibody: 2.5 x 104 s; Table 1 ).
The monovalent MOC-31 scFv has a three times lower off-rate than the bivalent 323/A3 antibody and is the best antibody of the present series. The off-rate of MOC-161 scFv is significantly higher (2.05 x 10-3 s-'), but still compares well to with those of the whole (bivalent) antibodies 323/A3 (1.06 x 10-3 s-') and 17-lA (38.2 x 10-3 S-1).
DISCUSSION
We compared the kinetics of binding of four well-characterized antibodies directed to the pancarcinoma antigen EGP-2, using SPR in a BlAcore ( Figure IA and Table 1 ). The MOC-31 whole antibody has by far the lowest apparent off-rate. To account for the avidity of the bivalent MOC-3 1 antibody, we also determined the kinetics of binding of the bispecific antibody Bis-1. As can be seen in Table 1 , the absence of a second EGP-2 binding site in Bis-1 is reflected in a fivefold increase in off-rate (Koff = 2.5x l0-4 s') when compared with MOC-3 1 whole bivalent antibody. As only apparent kinetic constants were obtained, it is difficult to compare our data with affinity values that have been reported for the antibodies [17-lA: 7x107 M-1 (Herlyn et al, 1986 ) and 323/A3: 2xI09 M-l (Velders et al, 1995) ]. However, dividing the on-rate of the MOC-31 whole antibody by the off-rate of the monovalent interaction (Bis-1) gives an affinity value of 4.2x108 M-l for this antibody (Table 1) . As the off-rate of the MOC-3 1 antibody is by far the lowest and the on-rates of MOC-3 1 and 323/A3 differ only by a factor of 2, the affinity of MOC-3 1 is expected to be higher than that of 323/A3. Unexpectedly, however, the value we find for MOC-3 1 is approximately fivefold lower than the one reported for 323/A3 (Velders et al, 1995) , which may be due to the different experimental set-up used (cell binding vs SPR analysis in a BlAcore). We cannot exclude an effect of the different glycosylation of the recombinant antigen as compared with the antigen present on human tumours on the kinetic parameters we measured. However, there are strong indications that the differences in offrate we measured are genuine, as affinity differences were also found by means of Scatchard analysis on a human cell line (Velders et al, 1994) .
The short half-life of the 17-lA-antigen complex (18 s for the bivalent antibody) explains the inefficient in vivo tumour targeting of this antibody (Velders et al, 1995) , but also suggests that the clinical responses obtained with this antibody may be largely caused by factors other than tumour accretion (e.g. the immunogenicity of this antibody). Indeed, treatment of colorectal carcinoma patients with an anti-idiotype antibody to the 17-1 A antibody has been shown to result in a humoral as well as a cellular immune response to the EGP-2 antigen (Fagerberg et al, 1995) .
The use of the phage display system was necessary to retrieve binding MOC-31 scFv clones; we had to perform two rounds of phage selection of a mini-repertoire to find MOC-31 binding scFvs. When cloning V-genes from hybridomas, a certain percentage (typically 50-95%) of non-binding or non-functional scFvs may be generated because of errors introduced during PCR amplification of the genes, Ig mRNA contribution of the myeloma fusion partner, alterations in the genes introduced by the primer set used, cloning artefacts [e.g. deletions, recombinations, insertions or frameshifts (for review, see Bradbury et al, 1995) ] or a combination of these factors. Furthermore, the antigen-binding surface might be slightly distorted or deformed by the introduction of a linker sequence between the VH and VL domains. The use of cloning vectors that allow expression of both secreted soluble scFv molecules and of phage displayed antibodies is therefore recommended for hybridoma V-gene cloning.
Using an in vitro model system (Roovers et al, in preparation), we could estimate the enrichment factor of specific MOC-31 phage over non-binding phage to be 150 per selection round, which means that the estimated starting frequency of functional MOC-3 1 scFv in the small library was at least 1 in 135 000. This very low frequency of functional MOC-3 1 scFv necessitated the use of the phage display system to retrieve binding clones, an observation that has also been reported by others (Krebber et al, 1997) .
The sequences of MOC-3 1 and MOC-161 antibody V-genes are different from the previously cloned anti EGP-2 antibodies (17-IA: Caton, 1986; 323/A3: Velders et al, 1994) . MOC-31 is very similar to 323/A3 in both heavy and light chain sequences: there are 11 amino acid differences for VH and three for Vic, with an additional six and two silent mutations, respectively, in the nonprimer encoded sequences. The CDR3 of the heavy chain is different, but equal in length; the CDR3 of the light chains are identical. The MOC-161 VH, in contrast, shows a higher homology to 17-IA (with 22 amino acid differences in the non primer-encoded V-gene segment) than to MOC-31 or 323/A3; its VK is very different from all other reported sequences (Table 3) . It is intriguing that all anti-EGP-2 antibodies studied here use VH segments with a CDR3 length of six or seven residues. These homologies may be a reflection of the fact that all four antibodies bind to the same immunodominant epitope on EGP-2.
We have tested the specificity of the cloned antibody fragments by means of an ELISA on six different antigens (EGP-2, tetanus toxoid, BSA, Marvel, lysozyme and streptavidin: data not shown). In addition, the fine specificity was confirmed using immunohistochemical staining of human carcinoma (Figure 4) . Thus, the cloning procedure itself did not alter the epitope recognition of the antibodies.
To use the isolated scFvs in tumour-targeting studies, antibody fragments with very low off-rates are required, as the loss of avidity of these monovalent fragments combined with their rapid clearance from blood leads to reduced retention in the tumour (Adams et al, 1993) . It can be calculated that for efficient tumour retention, off-rates in the region of 10-5 S-l or better are required (Schier et al, 1996) , yielding a half-life of bound complexes of 19 h or longer. As the MOC-3 1 antibody V-genes were cloned in a phagemid vector allowing expression on phage, it is possible to affinity mature the antibody fragments (and in particular the offrate), for example by chain shuffling or by random mutagenesis of the genes (for review, see Winter et al, 1994) .
Alternatively, rather than affinity maturation, more avid molecules such as bivalent or multivalent versions of MOC-31 scFv may be made (for review, see Holliger et al, 1993) . A second antigen binding site in the same molecule creates a large avidity effect, which makes the apparent affinity of such bivalent antibody species much higher. ScFv dimers, including non-covalently associated diabodies, have indeed been reported to show superior imaging characteristics of solid tumours than their monovalent counterparts (Adams et al, 1993; Tai et al, 1995; Wu et al, 1996) , mainly because of the slower off-rate of these avid molecules. Our cloned scFv antibody fragments already show a variable degree of
